Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001388
Filing Date
2025-06-02
Accepted
2025-05-30 21:45:08
Documents
34
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q limn-20250331x10q.htm   iXBRL 10-Q 324300
2 EX-31.1 limn-20250331xex31d1.htm EX-31.1 13137
3 EX-32.1 limn-20250331xex32d1.htm EX-32.1 6828
  Complete submission text file 0001410578-25-001388.txt   1559102

Data Files

Seq Description Document Type Size
4 EX-101.SCH limn-20250331.xsd EX-101.SCH 16927
5 EX-101.CAL limn-20250331_cal.xml EX-101.CAL 9207
6 EX-101.DEF limn-20250331_def.xml EX-101.DEF 40596
7 EX-101.LAB limn-20250331_lab.xml EX-101.LAB 118812
8 EX-101.PRE limn-20250331_pre.xml EX-101.PRE 80842
37 EXTRACTED XBRL INSTANCE DOCUMENT limn-20250331x10q_htm.xml XML 92170
Mailing Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623
Business Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623 213-273-5453
Liminatus Pharma, Inc. (Filer) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42626 | Film No.: 251012929
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)